Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux

Background and aims: While patients with Barrett’s oesophagus develop oesophageal adenocarcinoma more frequently than the general population, it has controversially been suggested that gastro-oesophageal reflux (GORD) itself is a more important determinant of risk. In order to assess the validity of this suggestion, we examined the risk of oesophageal cancer in patients with Barrett’s and with GORD compared with the general population in a community based cohort study. Methods: Cohorts of patients with Barrett’s (n = 1677), oesophagitis (n = 6392), and simple reflux (n = 6328), and a reference cohort (n = 13416) were selected from the General Practice Research Database. The last three cohorts were matched to the Barrett’s cohort by general practitioner practice, age, and sex. Cox’s regression analysis was used to calculate relative risks for oesophageal cancer. Standardised incidence ratio methodology was used to estimate the relative risks for oesophageal adenocarcinoma. Results: A total of 137 oesophageal cancers were identified, of which 94 prevalent cases were excluded. The hazard ratios for oesophageal cancer were 10.6 (5.1–22.0), 2.2 (0.9–5.2), and 1.7 (0.7–4.5) in the Barrett’s, oesophagitis, and reflux cohorts compared with the reference cohort, respectively. The corresponding relative risks for oesophageal adenocarcinoma were 29.8 (9.6–106), 4.5 (1.04–19.6), and 3.1 (0.6–14.2). Conclusion: Barrett’s oesophagus increases the risk of oesophageal cancer approximately 10 times and oesophageal adenocarcinoma approximately 30 times compared with the general population. There is only a modestly increased risk of oesophageal cancer in patients with reflux who have no record of Barrett’s oesophagus. Our findings therefore do not support the suggestion that gastro-oesophageal reflux disease itself predisposes to cancer.

[1]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[2]  H. Parkman,et al.  Heartburn--a serious symptom. , 1999, The New England journal of medicine.

[3]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[4]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[5]  K. Moghissi,et al.  Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study. , 1993, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  S. Tretli,et al.  Esophageal and gastric carcinoma in Norway 1958‐1992: Incidence time trend variability according to morphological subtypes and organ subsites , 1997, International journal of cancer.

[7]  W. Bilker,et al.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease , 2002, Pharmacoepidemiology and drug safety.

[8]  P. McKinney,et al.  Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland , 2000, British Journal of Cancer.

[9]  B. Johnston The significance of heartburn. , 2000, QJM : monthly journal of the Association of Physicians.

[10]  R. W. Armstrong,et al.  Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. , 1996, International journal of epidemiology.

[11]  J. Sloan,et al.  The incidence of adenocarcinoma in Barrett's oesophagus and an evaluation of endoscopic surveillance , 1991 .

[12]  F. Ellis,et al.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.

[13]  E. Achkar,et al.  The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. , 1988, The American journal of gastroenterology.

[14]  J. Blankensteijn,et al.  Adenocarcinoma in Barrett's oesophagus: an overrated risk. , 1989, Gut.

[15]  E. Kivilaakso,et al.  Adenocarcinoma arising in Barrett's esophagus , 1989, Digestive Diseases and Sciences.

[16]  R. Sampliner,et al.  Correlation of oesophageal acid exposure with Barrett's oesophagus length , 2001, Gut.

[17]  I. Braghetto,et al.  Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. , 1998, Surgery.

[18]  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma , 1999 .

[19]  P. Pairolero,et al.  Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? , 1996, The Journal of thoracic and cardiovascular surgery.

[20]  L J Schouten,et al.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. , 2000, International journal of epidemiology.

[21]  J. Jankowski Adenocarcinoma and Barrett's oesophagus. , 1992, Gut.

[22]  G. Morales,et al.  Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long‐term results of a prospective study , 1996, The British journal of surgery.

[23]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[24]  H. Smart,et al.  Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.

[25]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[26]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[27]  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1996 .

[28]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[29]  J. Hardcastle,et al.  Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. , 1992, Gut.

[30]  F. Ellis,et al.  Endoscopic surveillance of barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer , 1998, American Journal of Gastroenterology.

[31]  A. Schned,et al.  The Development of Dysplasia and Adenocarcinoma During Endoscopic Surveillance of Barrett’s Esophagus , 1998 .

[32]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[33]  A. Gavin,et al.  Risk of adenocarcinoma in Barrett's oesophagus: population based study , 2003, BMJ : British Medical Journal.

[34]  V. Eckardt,et al.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. , 2001, The American journal of medicine.

[35]  G. Lapertosa,et al.  Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme , 1997, European journal of gastroenterology & hepatology.

[36]  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999 .

[37]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[38]  P. Sparén,et al.  Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden , 1993, International journal of cancer.

[39]  G. Launoy,et al.  Changing pattern of oesophageal cancer incidence in France. , 1994, International journal of epidemiology.

[40]  B. Cooper,et al.  Barrett's oesophagus: a clinical study of 52 patients. , 1987, The Quarterly journal of medicine.

[41]  R. Cherian,et al.  Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. , 1997, The American journal of gastroenterology.